Caris Life Sciences, Inc.’s (NASDAQ:CAI) Lock-Up Period Set To Expire on December 15th

Caris Life Sciences’ (NASDAQ:CAI) lock-up period is set to expire on Monday, December 15th. Caris Life Sciences had issued 23,529,412 shares in its initial public offering on June 18th. The total size of the offering was $494,117,652 based on an initial share price of $21.00. After the expiration of Caris Life Sciences’ lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

Wall Street Analysts Forecast Growth

CAI has been the topic of several research analyst reports. Wall Street Zen lowered Caris Life Sciences from a “buy” rating to a “hold” rating in a research report on Saturday. Canaccord Genuity Group initiated coverage on Caris Life Sciences in a report on Tuesday, December 2nd. They set a “hold” rating and a $28.00 price target on the stock. Finally, Weiss Ratings began coverage on shares of Caris Life Sciences in a research report on Thursday, December 4th. They set a “sell (d)” rating for the company. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Caris Life Sciences has an average rating of “Reduce” and an average price target of $28.00.

Caris Life Sciences Stock Down 4.3%

Shares of Caris Life Sciences stock opened at $27.15 on Wednesday. Caris Life Sciences has a 52 week low of $22.86 and a 52 week high of $42.50.

Caris Life Sciences Company Profile

We are a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer. We develop and commercialize innovative solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Our entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets.